- Hydrix (HYD) receives approval from the Health Services Authority of Singapore to market and distribute the Guardian device in the country
- Singapore is the fourth country that has approved the use of the Guardian, joining the US, New Zealand and Malaysia, with approvals pending for Australia and Thailand
- Prior to this approval, the Guardian device was available under special access arrangements which were applied for by individual surgeons
- The Guardian device uses machine learning algorithms and artificial intelligence to continuously monitor the patient’s heart signal
- Shares in Hydrix are up 4.76 per cent and trading at 11 cents at 11:51 am AEST
Hydrix (HYD) has received approval from the Health Services Authority of Singapore (HSA) to market and distribute the Guardian device in the country.
The Guardian device uses machine learning algorithms and artificial intelligence to continuously monitor the patient’s heart signal and warn of any coronary syndromes such as silent heart attacks.
Singapore is the fourth country that has approved the use of the Guardian, joining the United States, New Zealand and Malaysia. Approvals are pending for Australia and Thailand.
Prior to this approval, the Guardian device was available under special access arrangements which were applied for by individual surgeons.
Dr Leslie Lam, a cardiologist at The Farrer Cardiac Centre in Singapore, has successfully performed eight implants since August 2020.
Hydrix Director of Sales & Operations Vickie Edwards said tthe approval represents a “key milestone” for the company.
“This approval enables application for inclusion on the Table of Surgical Procedures (TOSP), a list of procedures for which MediSave/MediShield Life insurance reimbursement can be claimed. Until inclusion on the TOSP, patients can undertake the operation at their own cost,” she said.
Shares in Hydrix were up 4.76 per cent and trading at 11 cents at 11:51 am AEST.